Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449982 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8HDAC6PIK3C3MAP4K1 | |
| SCHEMBL4458253 | 0.83 | PDE3B (0.41) | HDAC1HDAC8HDAC6PIK3C3MAP4K1 | |
| SCHEMBL4474713 | 0.80 | PDE3B (0.39) | S1PR1S1PR3PDE3BPDE3A | |
| SCHEMBL6871051 | 0.74 | NOTUM (0.44) | MAP4K1 | |
| SCHEMBL8585033 | 0.74 | NOTUM (0.44) | MAP4K1 | |
| SCHEMBL6883044 | 0.74 | NOTUM (0.44) | MAP4K1 | |
| SCHEMBL2732936 | 0.74 | NOTUM (0.43) | PIK3C3 | |
| SCHEMBL4452503 | 0.74 | P2RX7 (0.39) | HDAC1HDAC8HDAC6S1PR1S1PR3 | |
| SCHEMBL14313872 | 0.73 | PIK3C3 (0.48) | HDAC1HDAC8HDAC6PIK3C3MAP4K1 | |
| SCHEMBL13278809 | 0.71 | IDH1 (0.39) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | HDAC1 405/4885HDAC8 541/4885HDAC6 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.